Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | CMO, Hematology | December 14, 2021 | December 16, 2021 |
| Prelude Therapeutics IncPRLD · Entity 5561 | President, CMO | October 04, 2025 | October 07, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date December 14, 2021 · Filed December 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-12-14 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 2 · 2021-12-14 · Exercise / conversion · Acquired 1,500 · Balance 1,500 F1: Each American Depositary Share represents 13 Ordinary Shares. Row 3 · 2021-12-14 · Sale · Disposed 300 · Balance 1,200 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 4 · 2021-12-14 · Sale · Disposed 300 · Balance 900 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 5 · 2021-12-14 · Sale · Disposed 500 · Balance 400 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 6 · 2021-12-14 · Sale · Disposed 100 · Balance 300 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. Row 7 · 2021-12-14 · Sale · Disposed 200 · Balance 100 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 8 · 2021-12-14 · Sale · Disposed 100 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 · Expires 2029-06-04 | Direct | 211,276 |
Reported balance
After 2021-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-14 · Exercise / conversion · Disposed 19,500 · Balance 211,276 F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 160,055 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 160,055 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.
Prelude Therapeutics Inc
Report date October 04, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,917 |
Ending reported balance
After 2025-10-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-04 · Exercise / conversion · Acquired 9,375 · Balance 90,272 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Row 2 · 2025-10-04 · Tax withholding · Disposed 3,355 · Balance 86,917 F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,750 |
Reported balance
After 2025-10-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-04 · Exercise / conversion · Disposed 9,375 · Balance 18,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,500 | $132.83 | $332,075.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 5,130 | $29.49 | $151,283.70 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 5,000 | $45.31 | $226,550.00 |
DisclosureSEC source: 0001651308-19-000074 · wf-form4_156460344979901.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| June 27, 2019 Filed Jul 2, 2019 00:30 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3 | $126.33 | $378.99 |
DisclosureSEC source: 0001651308-19-000072 · wf-form4_156202740040079.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. Read SEC document |
| June 27, 2019 Filed Jul 2, 2019 00:30 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 427 | $124.50 | $53,162.95 |
DisclosureSEC source: 0001651308-19-000072 · wf-form4_156202740040079.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 462,579 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000061 · wf-form4_155993868234485.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,579 Underlying: Ordinary Shares · 462,579 shares Expires 2029-06-04 F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 62,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000061 · wf-form4_155993868234485.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,463 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| May 21, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 28,600 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · derivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,965 Underlying: Ordinary Shares · 28,600 shares Expires 2027-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F5 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| May 21, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,200 | $130.06 | $286,131.56 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| May 21, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 2,200 | $45.31 | $99,682.00 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| May 20, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · derivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,565 Underlying: Ordinary Shares · 3,900 shares Expires 2027-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F5 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| May 20, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $130.12 | $39,036.00 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 20, 2019 Filed May 22, 2019 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 300 | $45.31 | $13,593.00 |
DisclosureSEC source: 0001651308-19-000048 · wf-form4_155856627544082.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 183,690 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · derivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,465 Underlying: Ordinary Shares · 183,690 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 147 | $145.94 | $21,453.17 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.67 to $146.04, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,281 | $144.90 | $185,617.41 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.49 to $145.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,304 | $143.72 | $331,132.49 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.32 to $144.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,159 | $142.73 | $879,059.90 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.32 to $143.25, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,439 | $141.80 | $487,661.55 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,891 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.30 to $142.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 800 | $140.49 | $112,390.00 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,330 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.10 to $141.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 22:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 14,130 | $29.49 | $416,693.70 |
DisclosureSEC source: 0001651308-19-000035 · wf-form4_155493609515345.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 23:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 33,345 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-19-000025 · wf-form4_155234748424089.xml · derivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,155 Underlying: Ordinary Shares · 33,345 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 23:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,565 | $130.00 | $333,450.00 |
DisclosureSEC source: 0001651308-19-000025 · wf-form4_155234748424089.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 23:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 2,565 | $29.49 | $75,641.85 |
DisclosureSEC source: 0001651308-19-000025 · wf-form4_155234748424089.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F4 · price: The exercise price is reflected in ADSs. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 23:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 71 | $140.50 | $9,975.57 |
DisclosureSEC source: 0001651308-19-000025 · wf-form4_155234748424089.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · shares: These shares were acquired under the BeiGene, Ltd. Second Amended and Restated Employee Share Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 00:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 39,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-18-000009 · wf-form4_154345108513198.xml · derivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,328,500 Underlying: Ordinary Shares · 39,000 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 00:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,000 | $139.58 | $418,750.20 |
DisclosureSEC source: 0001651308-18-000009 · wf-form4_154345108513198.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.5334 to $140.5333, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 00:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 3,000 | $29.49 | $88,470.00 |
DisclosureSEC source: 0001651308-18-000009 · wf-form4_154345108513198.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · price: The exercise price is reflected in ADSs. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,911 | $174.60 | $508,246.92 |
DisclosureSEC source: 0001182489-18-000361 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.52 to $174.881, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 310,180 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001179110-18-009113 · edgar.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,180 Underlying: Ordinary Shares · 310,180 shares Expires 2028-06-25 F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 44,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009113 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,464 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001179110-17-015851 · edgar.xml · derivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,500 Underlying: Ordinary Shares · 1,367,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $98.00 | $98,000.00 |
DisclosureSEC source: 0001179110-17-015851 · edgar.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,000 | $29.51 | $29,510.00 |
DisclosureSEC source: 0001179110-17-015851 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001179110-17-015428 · edgar.xml · derivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,380,500 Underlying: Ordinary Shares · 1,380,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F4 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $94.53 | $18,906.00 |
DisclosureSEC source: 0001179110-17-015428 · edgar.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,300 | $94.21 | $122,474.82 |
DisclosureSEC source: 0001179110-17-015428 · edgar.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.50 to $94.49, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:05 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,500 | $29.51 | $44,265.00 |
DisclosureSEC source: 0001179110-17-015428 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 14:15 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,100 | $86.00 | $94,600.00 |
DisclosureSEC source: 0001179110-17-014878 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by The Jane Edna Huang Living Trust. F3 · ownership.nature: These securities are held by The Jane Edna Huang Living Trust. Read SEC document |
| November 20, 2017 Filed Nov 20, 2017 22:14 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $87.00 | $87,000.00 |
DisclosureSEC source: 0001179110-17-014377 · edgar.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by The Jane Edna Huang Living Trust. F3 · ownership.nature: These securities are held by The Jane Edna Huang Living Trust. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 22:14 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 600 | $85.00 | $51,000.00 |
DisclosureSEC source: 0001179110-17-014377 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by The Jane Edna Huang Living Trust. F3 · ownership.nature: These securities are held by The Jane Edna Huang Living Trust. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 22:54 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 980,465 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001179110-17-009794 · edgar.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980,465 Underlying: Ordinary Shares · 980,465 shares Expires 2027-06-26 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 21:13 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 1,400,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001179110-16-029407 · edgar.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Ordinary Shares · 1,400,000 shares Expires 2016-09-02 F1 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 21:13 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-029407 · edgar.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.